S-545-119
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sponsored by Catherine Cortez Masto (D-NV)
What it does
This bill would establish federal measures to address the illicit use of xylazine, a veterinary sedative increasingly found mixed with fentanyl and other street drugs. It would likely add xylazine to the federal controlled substances schedule, impose criminal penalties for its illegal distribution or possession, and direct federal agencies to coordinate on detection, enforcement, and public health responses. The bill is currently in the Senate Judiciary Committee after being ordered reported with an amendment.
Who benefits
People who use drugs and are at risk of xylazine exposure, particularly those in communities with high rates of fentanyl-laced street drugs, would benefit from increased awareness and potential harm-reduction resources. First responders and emergency medical personnel would benefit from clearer federal guidance on xylazine-related overdoses. Law enforcement agencies would gain new legal tools to prosecute illicit xylazine distribution. Communities with high overdose rates — disproportionately lower-income and urban areas — could see reduced drug supply contamination.
Who is hurt
Veterinarians, veterinary clinics, and agricultural operations that rely on xylazine as a legitimate animal sedative could face increased regulatory burdens, supply restrictions, or compliance costs if scheduling tightens access. Pharmaceutical distributors and manufacturers of xylazine for veterinary use could face new licensing or reporting requirements. Individuals found in possession of xylazine for non-medical purposes would face new or enhanced federal criminal penalties. Public defenders and legal aid organizations could see increased caseloads from new federal prosecutions.
Supporters argue
Supporters argue that xylazine poses a severe and growing public safety threat because it is not an opioid and therefore does not respond to naloxone (Narcan), the standard overdose reversal drug, making xylazine-laced drugs far more lethal. They contend that without federal scheduling, traffickers face no meaningful federal penalty for distributing xylazine, creating a dangerous legal gap. Supporters also argue that federal coordination is necessary because the crisis crosses state lines and local responses have been inconsistent. They maintain that legitimate veterinary access can be preserved through exemptions while still targeting illicit supply chains, and that acting now could prevent thousands of overdose deaths annually.
Opponents argue
Opponents argue that scheduling xylazine under federal controlled substances law could severely restrict access for veterinarians and farmers who depend on it as a safe, affordable, and widely used animal sedative — potentially harming animal welfare and raising costs for agricultural producers. They contend that criminalization alone has not reduced the supply of other scheduled substances and may drive xylazine further underground, making it harder to track and address. Critics also raise concerns that new criminal penalties would disproportionately affect low-level users and people with substance use disorders rather than major traffickers, and that a public health approach — such as expanded treatment and harm reduction — would more effectively reduce xylazine-related deaths.